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Supplementation with carotenoids is proposed to protect against age-related macular degeneration.
There is, however, considerable variability in retinal macular pigment response, which may be due to
underlying genetic variation. The purpose of this study was to determine whether genetic factors, which
have been previously associated with cross-sectional macular pigment levels in the retina or serum
lutein, also inﬂuence response to supplementation.
To this end we conducted an association study in 310 subjects from the TwinsUK cohort between
variants in 8 candidate genes and serum lutein and retinal macular pigment optical density (MPOD)
levels before and after supplementation. Four variants were associated with MPOD response to sup-
plementation (p < 0.05): rs11057841 (SCARB1), rs4926339 (RPE65), rs1929841 (ABCA1) and rs174534
(FADS1). We also conﬁrmed previous associations between rs6564851 near BMCO1 (p < 0.001) and
rs11057841 within SCARB1 (p ¼ 0.01) and baseline measures of serum lutein; while the latter was also
associated with MPOD response, none of the BMCO1 variants were. Finally, there was evidence for as-
sociation between variants near RPE65 and ELOVL2 and changes in lutein concentration after
supplementation.
This study is the ﬁrst to show association between genetic variants and response to carotenoids
supplementation. Our ﬁndings suggest an important link between MP response and the biological
processes of carotenoids transport and fatty acid metabolism.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Age-related macular degeneration (AMD) is the leading cause of
blindness in developed countries. Age is the most important
determinant, and common genetic polymorphisms are importanted Eye Disease Study; MP,
ptical density; LZ, lutein and
earch and Genetic Epidemi-
d Floor, South Wing, Block D,
mmond).
.r Ltd Open access under CC BY licensein its etiology (Evans, 2001; Fritsche et al., 2013; McCarty et al.,
2001). Oxidative stress has been implicated in AMD pathogenesis,
together with other risk factors such as smoking, obesity and hy-
pertension (Beatty et al., 2000; Evans, 2001; Hyman et al., 2000;
Johnson, 2005; Smith et al., 2001). Macular pigment (MP) may
play an important role in protecting the eye from accumulation of
oxidative species by absorbing blue light and thus reducing light-
induced oxidative stress, as well as having a direct antioxidant ef-
fect (Beatty et al., 2000; Margrain et al., 2004). MP represents the
accumulation of the carotenoids lutein (L) and zeaxanthin (Z), as
well as meso-zeaxanthin, a derivative of lutein. Lutein and zeax-
anthin (LZ) are xanthophyll carotenoid pigments which cannot be
synthesized de novo in mammals and are predominantly derived
from fruits and vegetables. Therefore, carotenoids-rich diets and LZ
dietary supplements have been proposed to protect against AMD
(Delcourt et al., 2006), and supplements have been tested in the.
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Although additional LZ supplementation to the AREDS1 formula-
tion did not signiﬁcantly reduce progression of AMD in the AREDS2
primary analysis, secondary analysis suggested that LZ supple-
mentation was protective against AMD progression in individuals
with low LZ dietary intake. Moreover, when LZ was given without
b-carotene there was a statistically signiﬁcant reduction in AMD
progression. This, and the fact that addition of b-carotene increases
the risk of lung cancer in former smokers, led the authors of the
AREDS2 study to conclude that LZ could be an appropriate carot-
enoid substitute in the AREDS formulation (AREDS2, 2013).
The accumulation of LZ in the macula is dependent on a variety
of factors e absorption, digestion, transport, retinal uptake, mac-
ular storage, degradation and secretion. However, little is known
about the extent to which genetic variation inﬂuences these
mechanisms. To our knowledge there are no studies on heritability
of serum xanthophyll levels, but there is data on heritability of
serum LZ concentration (between 67% and 85%) and on heritability
of macular pigment optical density (MPOD) response to LZ sup-
plementation (27%) (Hammond et al., 2012; Liew et al., 2005).
Genetic studies, both genome-wide association studies (GWAS) and
studies at a candidate gene level, have explored genetic factors that
underlie variation in serum LZ and MPOD measures, with some
success. There have been GWAS on plasma levels of carotenoids
alone (Ferrucci et al., 2009) and on AMD and circulating carotenoid
levels (Cipriani et al., 2012; Kopplin et al., 2010; Yu et al., 2011).
Ferrucci et al. (2009), in a GWAS of 1190 people, found signiﬁcant
associations between plasma levels of the carotenoids b-carotene
and lutein and SNPs mapping to BCMO1; the SNP rs6564851
explained 1.9% of variance. In a candidate gene study examining
plasma LZ levels in 302 healthy adult subjects, McKay et al. (2013)
found 5 of 47 variants in SCARB1 associated with serum L; only one
survived correction for multiple testing by permutation.
A recent study, in 1585 female participants of the Carotenoids
Age Related Eye Disease Study (CAREDS), investigated associations
between 440 SNPs in 26 candidate genes and MPOD (Meyers et al.,
2013). Variants in 11 genes were associated with MPOD and
collectively explained 5.1% of variance, though only rs11645428 in
BCMO1 survived Bonferroni correction for multiple testing.
Given that there is considerable variability in MPOD response in
the (generally small) supplementation studies (Connolly et al., 2011)
and that AREDS2 showed LZ supplementation to be effective in
absence of b-carotene (AREDS2, 2013), understanding the phar-
macogenetics of supplementation response is important to deter-
mine which groups of people might beneﬁt most from taking
supplements. Therefore, the aims of the current study were to
determine whether any of 12 variants in 8 genes previously asso-
ciated with MPOD or serum LZ inﬂuence MPOD and/or serum
response to LZ supplementation, and to replicate these associations.
2. Methods
2.1. Subjects
We studied 310 Caucasian female twins (79 monozygotic (MZ)
and 76 dizygotic (DZ) pairs), aged 20e50 years (mean: 39.72, SD:
8.40), free of ocular pathology, who were previously enrolled in a
prospective, non-randomized supplement study that aimed to es-
timate the heritability of macular response to LZ supplementation
(Hammond et al., 2012). Brieﬂy, participants were asked to take LZ
supplements with food (3 tablets per day of “Macuvite” (Spring-
ﬁeld, Oud-Beijerland, The Netherlands)) for a period of 6 months.
Each tablet contained 18 mg lutein and 2.4 mg zeaxanthin. The
compliancewas 90% at 3 months and 82% at six months (Hammond
et al., 2012). All individuals were unaware of eye research interestsat the time of enrollment and provided written informed consent.
The research was approved by the local ethics committee and
conducted in accordance with the tenets of the Declaration of
Helsinki.
2.2. Response measurements
Serum lutein and zeaxanthin levels were measured and
analyzed separately using reverse phase high performance liquid
chromatography while MPOD was measured by autoﬂuorescence
(AF). We assessed response to supplementation as change of serum
L and Z levels after 3 months of supplement intake and as change in
MPOD after 6 months of supplementation. These changes were
expressed as a rate of change as deﬁned by the ratio of the differ-
ence between the second and baseline measurements, divided by
the baseline measurement. MPOD at baseline and MPOD response
were approximately normally distributed and were not trans-
formed, but serum L and Z and the change in their levels underwent
logarithmic transformation. As L and Z were correlated (correlation
coefﬁcient of 0.61), we chose to analyze L only.
2.3. Genotyping data
The TwinsUK cohort, a subset of which was used in this study,
was previously genotyped using Illumina 610K/Illumina 317K chips
and later imputed against the CEU HapMap2 panel using IMPUTE 2
(Howie et al., 2009). All SNPs passed strict quality control (QC).
Brieﬂy, SNPs with minor allele frequency less than 5% and SNPs
showing deviation from HardyeWeinberg equilibrium (p < 104)
or high missingness were excluded. Individuals with non-
Caucasian ancestry, as detected by principal components analysis,
were excluded. After imputation, poorly imputed SNPs were also
excluded. The ﬁnal number of SNPs after the quality control step
was 2,287,998.
2.4. Statistical analysis
Ten of the 13 CAREDS MPOD-associated SNPs from their ﬁnal
multivariate model were tested (there were no data on rs6078
within LIPC and rs675679 within GSTP1; rs10744182 was excluded
because of low imputation quality) (Meyers et al., 2013). SNPs in
BCMO1 overlapped with SNPs in the GWAS of serum L (Ferrucci
et al., 2009), only rs6564851 was added to the analysis. Finally,
the SNP most strongly associated with serum LZ in the SCARB1
candidate gene study, rs11057841, was included (McKay et al.,
2013). This resulted in 12 SNPs in 8 genes being tested for associ-
ation for both MPOD and serum L response to supplementation
(Table 1). Where more than one SNP was tested per gene, those
SNPs were independent of one another (R2 < 0.80). Eight of the
analyzed SNPs were genotyped while rs11057841, rs838879,
rs10179921 and rs174534 were imputed. Age-adjusted association
analyses taking zygosity into account were performed using the
likelihood ratio test implemented in the Merlin software package.
SNPs with p < 0.05 were regarded as nominally signiﬁcant and
SNPs with p < 0.0019 as signiﬁcant after Bonferroni correction for
multiple testing (0.05/number of SNPs 2where 2 is the number of
independent traits tested i.e. L and MPOD).
3. Results
At baseline, the mean MPOD was 0.41 (SD ¼ 0.15) density units
and the mean lutein concentration in the blood was 0.121 mg/ml
(SD ¼ 0.05). The mean increase in MPOD after 6 months of sup-
plementationwas 3.7% (0.015 density units (SD ¼ 0.06)). The lutein
concentration at 3 months after supplementation had increased by
Table 1
Association results for change in lutein and MPOD after supplementation with Lutein and Zeaxanthin.
Gene SNP Chr. Position MAF Effect allele Lutein MPOD
Beta SE p-value Beta SE p-value
RPE65 rs4926339 1 68694879 0.42 A L0.04 0.016 0.01 0.029 0.014 0.04
ABCG5 rs10179921 2 43921795 0.05 A 0.237 0.23 0.3 0.023 0.028 0.4
ELOVL2 rs1150561 6 11071833 0.02 A L0.736 0.361 0.04 0.045 0.053 0.4
ABCA1 rs1929841 9 106587443 0.16 G 0.177 0.127 0.16 L0.041 0.016 0.01
FADS1 rs174534 11 61306034 0.38 G 0.001 0.1 0.99 0.032 0.015 0.03
SCARB1 rs838879 12 123827394 0.22 G 0.011 0.138 0.94 0.004 0.02 0.84
SCARB1 rs11057841 12 123882696 0.09 T 0.21 0.245 0.39 L0.078 0.033 0.02
SCARB1 rs4379922 12 123917069 0.27 G 0.085 0.109 0.43 0.008 0.013 0.54
BCMO1 rs11645428 16 79816397 0.33 A 0.133 0.115 0.25 0.01 0.014 0.48
BCMO1 rs6564851 16 79822098 0.46 G 0.036 0.104 0.73 0.009 0.014 0.51
BCMO1 rs6564863 16 79852394 0.43 T 0.04 0.102 0.7 0.001 0.0013 0.96
ALDH3A2 rs8069576 17 19510912 0.47 A 0.041 0.1 0.68 0.006 0.015 0.688
SNP e single nucleotide polymorphism; Chr. e chromosome; Position e physical position of variants is given according to NCBI Human Genome build 36; MAF eminor allele
frequency; beta e betas for change in lutein concentration are not back-transformed; SE e standard error; MPOD e macular pigment optical density; bold e SNPs reaching
nominal signiﬁcance.
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L concentration or MPOD between MZ and DZ twins at either point
(p > 0.05).
Four of the tested variants were associated withMPOD response
(Table 1). The most signiﬁcantly associated variant was rs1929841
(ABCA1) and the G allele at this variant was associated with poorer
MPOD response (p ¼ 0.01). Similarly, the T allele at rs11057841
(SCARB1) was associated with poor MPOD after supplementation
(p ¼ 0.02). Two other variants, rs4926339 (RPE65) and rs174534
(FADS1) were associated with better MPOD response after supple-
mentation (p ¼ 0.04 and p ¼ 0.03 respectively). Two of the tested
variants were associated with change in L concentration after
supplementation: rs4926339 (RPE65) and rs1150561 (ELOVL2) with
p ¼ 0.01 and p ¼ 0.04 respectively (Table 1). Of note, rs4926339
(RPE65) was associated with both MPOD and L response after
supplementation and with MPOD at baseline (Table 2).
At baseline, three variants were associated with MPOD:
rs4926339 (RPE65), rs6564851 (BCMO1) and rs6564863 (BCMO1)
with p ¼ 0.007, p ¼ 0.0018 and p ¼ 0.04 respectively. Only
rs6564851 survived correction formultiple testing (Table 2). Four of
the tested variants were associated with baseline lutein concen-
tration (Table 2). Three of these, rs11057841 (SCARB1), rs11645428
(BCM01) and rs6564863 (BCM01), were nominally associated
(p ¼ 0.01, p ¼ 0.03, and p ¼ 0.01 respectively), while rs6564851
(BCM01) was still signiﬁcant after correction for multiple testing
(p ¼ 0.0001). Of note, rs6564851 and rs6564863 were associated
with both MPOD and L at baseline (Table 2) while the T allele atTable 2
Association results for lutein and MPOD at baseline.
Gene SNP Chr. Position MAF Effect allele
RPE65 rs4926339 1 68694879 0.42 A
ABCG5 rs10179921 2 43921795 0.05 A
ELOVL2 rs1150561 6 11071833 0.02 A
ABCA1 rs1929841 9 106587443 0.16 G
FADS1 rs174534 11 61306034 0.38 G
SCARB1 rs838879 12 123827394 0.22 G
SCARB1 rs11057841 12 123882696 0.09 T
SCARB1 rs4379922 12 123917069 0.27 G
BCMO1 rs11645428 16 79816397 0.33 A
BCMO1* rs6564851 16 79822098 0.46 G
BCMO1 rs6564863 16 79852394 0.43 T
ALDH3A2 rs8069576 17 19510912 0.47 A
SNP e single nucleotide polymorphism; Chr. e chromosome; Position e physical position
frequency; betae betas for lutein are not back-transformed; SE e standard error; MPODe
SNPs reaching nominal signiﬁcance.rs11057841 (SCARB1) was related to higher baseline L, but poorer
macular response.
4. Discussion
This study is the ﬁrst, to our knowledge, to investigate the ge-
netics of retinal macular pigment response to supplementation
with carotenoids. In this relatively small study of 310 participants,
we found some evidence that rs4926339 (RPE65), rs1929841
(ABCA1), rs174534 (FADS1) and rs11057841 (SCARB1) may inﬂuence
theMPOD response to supplementation (p¼ 0.04, p¼ 0.01, p¼ 0.03
and p ¼ 0.02 respectively). These associations, however, were sig-
niﬁcant only at nominal statistical level, most probably due to the
modest power of our sample. We conﬁrmed with robust statistical
signiﬁcance the previous association reported between the variant
rs6564851 in BMCO1 and cross-sectional measures of serum L
(Ferrucci et al., 2009). We also replicated the association between
BMCO1 variants and cross-sectional MPOD (Meyers et al., 2013).
However, there was no evidence that rs6564851 or other BMCO1
variants inﬂuencedMPOD or serum L response to supplementation.
The rs11057841 (SCARB1) was also associated with MPOD
response; we and others have previously identiﬁed its association
with cross-sectional serum L levels (McKay et al., 2013). Although
we did not replicate all the associations from CAREDS (Meyers et al.,
2013), we did ﬁnd nominal association between rs4926339 (RPE65)
and rs6564863 (BCMO1) and MPOD at baseline (p ¼ 0.007 and
p ¼ 0.04 respectively). Moreover, rs11645428 (BCMO1), rs838879Lutein MPOD
Beta SE p-value Beta SE p-value
0.079 0.046 0.09 L0.041 0.015 0.007
0.114 0.095 0.23 0.045 0.031 0.14
0.078 0.164 0.63 0.003 0.013 0.82
0.02 0.008 0.72 0.004 0.02 0.84
0.073 0.046 0.11 0.017 0.015 0.27
0.019 0.053 0.72 0.014 0.018 0.45
0.252 0.173 0.01 0.024 0.035 0.49
0.077 0.046 0.1 0.023 0.016 0.16
0.101 0.046 0.03 0.025 0.016 0.12
L0.161 0.042 0.0001* L0.045 0.014 0.0018*
L0.038 0.015 0.01 0.03 0.014 0.04
0.048 0.042 0.25 0.016 0.014 0.27
of variants is given according to NCBI Human Genome build 36; MAF eminor allele
macular pigment optical density; * e signiﬁcant after Bonferroni correction; bolde
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the same direction and similar magnitude of effect on cross-
sectional MPOD as previously reported (Meyers et al., 2013).
For most complex traits, common variants involved in complex
phenotypes have relatively low effect sizes over their respective
traits (http://www.genome.gov/gwastudies/). Our study is only
modestly powered to detect them, as it was small (310 subjects)
and the MPOD response to LZ supplementation was weak
(Hammond et al., 2012). Despite this, we not only replicated vari-
ants that were previously associatedwith L levels orMPOD, but also
were able to detect variants associated with MPOD response to
supplementation. A larger study would have the power to detect
more associations and variants with smaller, but nonetheless
important, effects.
Three of the BCMO1 SNPs we tested were associated with
baseline L and two of those were also associated with baseline
MPOD (Table 2). Although the role of BCMO1 in carotene meta-
bolism is well studied, the role of this gene in xanthophyll meta-
bolism is unknown. BCMO1 encodes a carotenoid cleaving enzyme
which converts b-carotene to retinol (Lobo et al., 2012) e a process
that produces reactive oxygen species in the presence of oxidative
stress (Lobo et al., 2012; Siems et al., 2002). Although retinol is
essential for vision and for quenching free radicals, its metabolites
can also induce reactive species (Chen et al., 1999; Klamt et al.,
2003; Murata and Kawanishi, 2000). Assuming that carotenoids
concentration in the macula is regulated by mechanisms similar to
those in peripheral blood, rs6564851 alleles might affect the ﬁne
balance between these antioxidants and their potential harmful
metabolites. Also, there might be competition in absorption,
transport or clearance between b-carotene and LZ which favors b-
carotene, as suggested by co-administration experiments at high
doses (Kostic et al., 1995; Wang et al., 2010). We found no evidence
that common BMCO1 variants are involved in response to supple-
mentation, however.
At another variant of interest, rs11057841 (SCARB1), the T allele
was associated with increased L levels at baseline and also with a
larger increase in MPOD after supplementation e a potential pro-
tective effect for AMD. We have previously reported our replication
of the association between rs11057841 within SCARB1 and serum L
(McKay et al., 2013). Of note, in this study this variant was also
associated with MPOD response, a novel ﬁnding. SCARB1 encodes a
high density lipoprotein receptor, which plays an important role in
the metabolism of cholesterol and L in particular (Zerbib et al.,
2009), and may be involved in the formation of drusen and basal
deposits during the early stages of AMD (Curcio et al., 2011; Mullins
et al., 2000).
We found some suggestive association between a variant in
ABCA1 and MPOD response to supplementation (Table 2). ABCA1
encodes for an ATP-binding cassette which functions as a choles-
terol efﬂux pump (Schmitz and Langmann, 2001). In chicks,
recessivemutations in ABCA1 lead to reducedMPOD due to reduced
co-transport of LZ from the liver to the blood and from the blood to
the retina (Connor et al., 2007). Although a high L diet could rescue
the liver phenotype, the retinal LZ concentration remained low
(Connor et al., 2007). In humans, ABCA1 is expressed in the retinal
pigment epithelium, and when ABCA1 protein is inhibited, lipid
inﬂux is compromised (Duncan et al., 2009). The poor MPOD
response associated with the G allele in our study suggests that
these mechanisms may be important: carriers of the G allele not
only have lower MPOD but are less able to maintain LZ levels in
blood, so might not beneﬁt greatly from LZ supplementation.
We also found an association with a variant rs4926339 (RPE65)
which was previously linked to MPOD (Meyers et al., 2013). RPE65
encodes a retinal pigment epithelium protein, which is involved in
visual pigment regeneration (Lobo et al., 2012; Xue et al., 2004). Aby-product of this cycle is the ﬂuorescent bis-retinoid A2E, which
has a variety of toxic effects including increase in oxidative damage
(Kim et al., 2006; Zhou et al., 2006). Although RPE65 is a good
candidate gene for AMD, there are almost no data on the rela-
tionship between RPE65 and MPOD or L in serum, which makes it
difﬁcult to speculate on the mechanism behind our ﬁndings.
Further functional research is needed before any hypothesis can be
drawn.
In this study, rs174534 (FADS1) was associatedwith betterMPOD
response to supplementation (p ¼ 0.03). FADS1 encodes an enzyme
which catalyzes the conversion of plant-derived fatty acids to
eicosapentaenoic acid (EPA) (Tanaka et al., 2009). MPOD has been
previously associated not only with LZ but also with EPA and do-
cosahexaenoic acid (DHA) (Delyfer et al., 2012). Finally, rs1150561
near ELOVL2was associated with poorer L response. The product of
this gene catalyzes the elongation of EPA to DHA (Kobayashi et al.,
2007). Although our study suggests that ELOVL2 and FADS1 poly-
morphisms may also relate to L and MPOD response respectively,
the mechanism of this relationship is uncertain, but it is probably
connected to processes governing lipid composition in serum.
Apart from the sample size, a potential limitation of this study is
that our sample consisted of Caucasian women only. There is evi-
dence that individuals with African or Asian ancestry have higher
MPOD than Caucasian individuals (Wolf-Schnurrbusch et al., 2007;
Woo and Lee, 2002) and that there are ethnic differences in AMD
prevalence (Friedman et al., 1999; Kawasaki et al., 2010), but it is
unclear whether the response to LZ supplementation varies be-
tween ethnic groups. Macular pigment density differs between
men and women but there are no signiﬁcant sex differences in
plasma LZ concentration or dietary LZ intake (Curran-Celentano
et al., 2001; Hammond et al., 1996). There is some evidence of
gender differences in magnitude of MPOD response (Thurnham
et al., 2008). The prevalence of AMD in men and women is
similar, and there is no evidence that the mechanisms of AMD
pathogenesis are gender-dependent (Rudnicka et al., 2012). The
ﬁndings of this study, however, will require validation in other
studies including men and individuals from different ethnic back-
grounds, though the replication of previous data including men is
reassuring. Another point concerning generalizability is whether
twins are representative of the general population. The TwinsUK
cohort has been shown to be representative of the UK population
with respect to physical characteristics and susceptibility to com-
mon diseases (Andrew et al., 2001). The study was designed to
examine candidate SNPs underlying normal variation, so the sub-
jects included were healthy, without AMD. We believe that studies
of endophenotypes such as MPOD are highly relevant to end-stage
disease such as AMD.
To summarize, this study is the ﬁrst to show association be-
tween genetic variants andMP response to LZ supplementation and
to suggest an important link between processes such as carotenoids
transport and lipid metabolism and MP response to supplemen-
tation. Further investigation into the pharmacogenomics of LZ
supplementation would be worthwhile as it may identify which
groups of people are more likely to experience real beneﬁt from
taking supplements, as well as explaining why supplement studies
have shown considerable variability in supplement response. Un-
derstanding the pharmacogenomics of MP supplements may also
cast light on the processes involved in macular pigment physiology,
and in turn on those involved in AMD pathology.
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